banner
 
bar

program

slides
bar
 
 

Optimizing the Safety-Benefit Equation for Multiple Sclerosis

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

3.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in multiple sclerosis

Release Date

May 21, 2013

Expiration Date

May 21, 2015

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period May 21, 2013 through May 21, 2015, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all six segments totaling 3.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

logo Supported by an educational grant
from Teva Neuroscience.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

BRUCA CREE, MD, PhD, MCR
Program Chairman
Associate Professor of Clinical Neurology
University of California San Francisco
Clinical Research Director
UISCSD Multiple Sclerosis Center
San Francisco, CA

Grant/Research Support: Roche
Consultant/Advisory Board: Abbott, Biogen Idec, Genzyme, Medimmune, Novartis,
Sanofi-Aventis


BURK JUBELT, MD

Professor of Neurology, Microbiology/Immunology and Neuroscience
SUNY Upstate Medical University
Syracuse, NY

Research Support: Sanofi-Aventis Clinical Trials, Genzyme Clinical Trial, Biogen Clinical Studies, Novartis Clinical Trial
Consultant/Advisory Board: Biogen Clinical Studies, National MS Society, Upstate NY Chapter, MS Resources of Central NY



M. TARIQ BHATTI, MD

Associate Professor, Neuro-Ophthalmology
Departments of Ophthalmology and Medicine (Division of Neurology)
Duke University Eye Center and Duke University Medical Center
Durham, North Carolina

Speaker/Honoraria: EMD Serono, Pfizer, Novartis, Bayer Healthcare
Consultant/Advisory Board: Novartis



DANIEL KANTOR, MD

Medical Director
Neurologique
Ponte Vedra, FL

Research Support: Acorda, Avanir, Allergan, Merz, Medicis, US World Meds,
Genzyme, Questcor, Novartis, Osmotica, Teva, Biogen
Speaker/Honoraria: Acorda, Avanir, Allergan, Merz, Medicis, US World Meds,
Genzyme, Questcor, Novartis, Osmotica, Teva, Biogen,
Depomed
Consultant/Advisory Board: Acorda, Avanir, Allergan, Merz, Medicis, US World Meds,
Genzyme, Questcor, Novartis, Osmotica, Teva, Biogen

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  1. Identify the rationale for treating patients with MS with established injected agents shown to act through immunomodulating effects and actions that take place in the central nervous system;
  2. Explain the role of established injectable neuroimmunomodulating agents, the evolving role of oral neuroimmunomodulating agents for MS; and, how such agents, including established injectable IMTs, acting on both inflammatory and neurodegenerative dimensions of MS disease progression, may produce different clinical outcome end points, including improvements in EDSS and other disability end points, than agents acting on inflammatory dimensions of the disease only;
  3. Detail the variable actions and safety profiles of oral and injectable MS agents, including injectable IMTs, and develop a better and more scientifically rigorous appreciation for the difference among "anti-inflammatory" and "neuroprotective" properties of such agents; and their effects on such clinical end points as relapse rate, disability metrics, core health outcomes, and neuroimaging manifestations of neurodegeneration;
  4. Understand when, how, and if to make cross-trial comparisons among oral and injectable immune-modulating agents for MS, and how to interpret the findings of clinical trials with multiple primary and secondary end points and compare those findings to the LTFU data available for established platform injectable therapies;
  5. Understand the mechanistic differences and safety profiles among oral and injectable agents that are effective for reducing relapse rates versus those that have primarily or complementary neuroprotective properties as evidenced by change in MRI neurometrics, cerebral atrophy, and improved disability scales.

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2013 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC

 
6

 

Key Program Topics Include:

ACT
alemtuzumab
Avonex
Axonal
Azathioprine
Behçet
BENEFIT
betaseron
BEYOND
Brain Atrophy
brain stem
CD4+ T
cerebellum,
spinal cord
cerebral cortex
Cladribine
CHAMPIONS
CHAMPS/ETOMS

Copaxone
Corticosteroids
Cyclophosphamide
daclizumab
Demyelination
DMD
EDSS
EVIDENCE
Fingolimod
Glatiramer acetate
HIV
HTLV-1
Human IgG4IFN b-1a
IFN b-1b
Immunosuppression
Laquinimod
INCOMIN

Interferon
Lesions
Lyme disease
Methotrexate
Mitoxantrone
MRI
Multiple Sclerosis
relapsing-remitting MS
Mycophenolate mofetil
Natalizumab
neuritic transection
neurodegenerative
Neuroimmunomodulating
neuroimmunomodulation
Neurosyphilis
NIMO
NMSS
Novantrone

optic nerves
periventricular
PML
PRECISE
PRISMS
Rebif
REGARD
rituximab
RRMS
Sarcoidosis
Selective adhesion molecule inhibitor
Sjögren syndrome
Statins
Teriflunomide
Tysabri
white matter